dc.creatorGarcía Canclini, Néstor
dc.creatorPorta, Daniela Josefina
dc.creatorAlasino, Roxana Valeria
dc.creatorMuñoz, Sonia Edith
dc.creatorBeltramo, Dante Miguel
dc.date.accessioned2020-07-24T14:49:32Z
dc.date.accessioned2022-10-15T12:26:18Z
dc.date.available2020-07-24T14:49:32Z
dc.date.available2022-10-15T12:26:18Z
dc.date.created2020-07-24T14:49:32Z
dc.date.issued2020-11
dc.identifierGarcía Canclini, Néstor; Porta, Daniela Josefina; Alasino, Roxana Valeria; Muñoz, Sonia Edith; Beltramo, Dante Miguel; Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution; Elsevier; Medical Hypotheses; 144; 11-2020; 1-3; 110079
dc.identifier0306-9877
dc.identifierhttp://hdl.handle.net/11336/110164
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4385842
dc.description.abstractThe traditional formulation of ibuprofen is poorly soluble in water, so the administered dose must be 10 times higher than the dose required for a therapeutic effect. The development of a hydrosoluble form of ibuprofen can be a strategy to reach a high concentration in the lungs by using modern inhalation devices. Therefore, the development of an inhalable formulation with high bioavailability in the lungs was the leitmotiv of our investigation. The hypertonic ibuprofen solution to be nebulized (NIH) presents great relevant characteristics: bactericidal, virucidal, mucolytic and has a known anti-inflammatory property. Bactericidal and virucidal effects are related to the physico-chemical properties of Na-ibuprofenate as an amphipathic molecule. It has the capability to insert into the bilayer membranes destabilizing the structure, altering its biological properties and avoiding the duplication or infection. Our preliminary results indicate that the presence of this high ionic strength solution reduces 10 times the amount of ibuprofen necessary to kill bacteria, but also the time to kill 1x106 bacteria, from 4 h (in its absence) to only three minutes (in its presence). That was observed using Pseudomona aeruginosa, methicillin-resistant Staphylococcus aureus and Burkholderia cepacia. Also, ?in vitro´´ ibuprofen demonstrated virucidal activity against the so-called enveloped virus, a family that includes coronavirus strain (2019-nCoV). We observed too, the markedly reduced local inflammation in the airways after administering NIH lays on its ability to inhibit the enzyme cyclooxygenase and to markedly diminish reactive oxygen species (ROS). Other investigators also showed the importance of actin in the rapid spread of virus infection. Furthermore, reorganization of the actin filaments is a key step in lung inflammation induced by systemic inflammatory responses caused by SARS-CoV-2. These findings suggest that the interaction between actin proteins and S1 is involved in the 2019-nCoV infection and pathogenesis.Consequently, the possibility of interfering in this interaction could represent a valid hypothesis for the development of promising therapeutic and prevention strategies. In conclusion, we consider that treating people with COVID-19 with NIH may be beneficial and an opportunity to contribute for the current global health emergency.
dc.languageeng
dc.publisherElsevier
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0306987720320077
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.mehy.2020.110079
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340056/
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectIBUPROFEN
dc.subjectPNEUMONIA
dc.subjectSARS-CoV-2
dc.subjectANTIVIRAL
dc.subjectANTIINFLAMATORY
dc.titleIbuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución